Trevi Therapeutics (TRVI) Stock Forecast & Price Target

Compare

500 Followers

See the Price Targets and Ratings of:

All Analysts

Top Analysts

Premium

TRVI Analyst Ratings

Strong Buy

9 Buy

0 Hold

0 Sell

Based on 9 analysts giving stock ratings to

Trevi

Therapeutics

in the past 3 months

TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months

TRVI Stock 12 Month Forecast

Average Price Target

$21.67

▲(262.37%Upside)

Based on 9 Wall Street analysts offering 12 month price targets for Trevi Therapeutics in the last 3 months. The average price target is $21.67 with a high forecast of $29.00 and a low forecast of $13.00. The average price target represents a 262.37% change from the last price of $5.98.

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"1":"$1","30":"$30","8.25":"$8.25","15.5":"$15.5","22.75":"$22.8"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":29,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$29.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":21.67,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$21.67</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":13,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$13.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[1,8.25,15.5,22.75,30],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Oct<br/>2024","6":"Jan<br/>2025","9":"Apr<br/>2025","12":"Jul<br/>2025","25":"Jul<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,5.7,7.492307692307692,9.284615384615385,11.076923076923077,12.86923076923077,14.661538461538463,16.453846153846154,18.246153846153845,20.03846153846154,21.83076923076923,23.623076923076923,25.415384615384614,27.20769230769231,{"y":29,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,5.7,6.928461538461539,8.156923076923078,9.385384615384616,10.613846153846154,11.842307692307694,13.070769230769233,14.299230769230771,15.527692307692309,16.756153846153847,17.984615384615388,19.213076923076926,20.441538461538464,{"y":21.67,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,5.7,6.2615384615384615,6.823076923076924,7.384615384615385,7.946153846153846,8.507692307692308,9.069230769230769,9.630769230769232,10.192307692307693,10.753846153846155,11.315384615384616,11.876923076923077,12.438461538461539,{"y":13,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":2.89,"date":1719792000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.1,"date":1722470400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.16,"date":1725148800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.11,"date":1727740800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 22,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.01,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 19,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.86,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 29,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4.12,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 24,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.94,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 22,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4.52,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 24,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":6.01,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 23,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":6.9,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 32,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":6.32,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 23,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":5.7,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 21,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Highest Price Target$29.00

Average Price Target$21.67

Lowest Price Target$13.00

The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts

Joshua SchimmerCantor Fitzgerald

Cantor Fitzgerald

$25

Buy

318.06%

Upside

Initiated

07/01/25

Trevi Therapeutics initiated with an Overweight at Cantor FitzgeraldTrevi Therapeutics initiated with an Overweight at Cantor Fitzgerald

Faisal KhurshidLeerink Partners

Leerink Partners

$11→$13

Buy

117.39%

Upside

Reiterated

06/11/25

Trevi Therapeutics: Positive Developments and Financial Strength Support Buy Rating

Leland GershellOppenheimer

Oppenheimer

$20→$23

Buy

284.62%

Upside

Reiterated

06/03/25

Trevi Therapeutics price target raised to $23 from $20 at OppenheimerTrevi Therapeutics price target raised to $23 from $20 at Oppenheimer

Brandon FolkesH.C. Wainwright

H.C. Wainwright

$21

Buy

251.17%

Upside

Reiterated

06/03/25

Promising Phase 2b Results for Haduvio in IPF-CC Drive Buy Rating and Highlight Market Potential

Debanjana ChatterjeeJonesTrading

JonesTrading

$25

Buy

318.06%

Upside

Reiterated

06/02/25

Buy Rating for Trevi Therapeutics Driven by Promising Haduvio Trial Results and Market Opportunities

Ryan DeschnerRaymond James

Raymond James

$29

Buy

384.95%

Upside

Reiterated

06/02/25

Raymond James Reaffirms Their Buy Rating on Trevi Therapeutics (TRVI)

Annabel SamimyStifel Nicolaus

Stifel Nicolaus

$15

Buy

150.84%

Upside

Reiterated

06/02/25

Buy Rating for Trevi Therapeutics: Promising Phase 2b Results for Haduvio in IPF-CC

Serge BelangerNeedham

Needham

$24

Buy

301.34%

Upside

Reiterated

06/02/25

Analysts Offer Insights on Healthcare Companies: Olema Pharmaceuticals (NASDAQ: OLMA) and Trevi Therapeutics (NASDAQ: TRVI)

Mayank MamtaniB.Riley Financial

B.Riley Financial

$20

Buy

234.45%

Upside

Reiterated

05/21/25

B.Riley on Trevi Therapeutics (TRVI): Remain Buyers into Imminent Ph2b CORAL ReadoutB.Riley analyst Mayank Mamtani reiterated a Buy rating and $20.00 price target on Trevi Therapeutics (NASDAQ: TRVI).

Kaveri PohlmanClear Street

Clear Street

$11

Buy

83.95%

Upside

Reiterated

03/06/25

Clear Street reiterates Buy Rating on Trevi Therapeutics (TRVI)Clear Street analyst Kaveri Pohlman reiterated a Buy rating and $11.00 price target on Trevi Therapeutics (NASDAQ: TRVI)

Jason KolbertD. Boral Capital

D. Boral Capital

$21

Buy

251.17%

Upside

Reiterated

10/04/24

EF Hutton reiterates Buy Rating on Trevi Therapeutics (TRVI)EF Hutton analyst Jason Kolbert reiterated a Buy rating and $21.00 price target on Trevi Therapeutics (NASDAQ: TRVI).

Ranks

Any

Analyst Rating

Any

Upside/ Downside

Any

Action

Any

Joshua SchimmerCantor Fitzgerald

Cantor Fitzgerald

$25

Buy

318.06%

Upside

Initiated

07/01/25

Trevi Therapeutics initiated with an Overweight at Cantor FitzgeraldTrevi Therapeutics initiated with an Overweight at Cantor Fitzgerald

Faisal KhurshidLeerink Partners

Leerink Partners

$11→$13

Buy

117.39%

Upside

Reiterated

06/11/25

Trevi Therapeutics: Positive Developments and Financial Strength Support Buy Rating

Leland GershellOppenheimer

Oppenheimer

$20→$23

Buy

284.62%

Upside

Reiterated

06/03/25

Trevi Therapeutics price target raised to $23 from $20 at OppenheimerTrevi Therapeutics price target raised to $23 from $20 at Oppenheimer

Brandon FolkesH.C. Wainwright

H.C. Wainwright

$21

Buy

251.17%

Upside

Reiterated

06/03/25

Promising Phase 2b Results for Haduvio in IPF-CC Drive Buy Rating and Highlight Market Potential

Debanjana ChatterjeeJonesTrading

JonesTrading

$25

Buy

318.06%

Upside

Reiterated

06/02/25

Buy Rating for Trevi Therapeutics Driven by Promising Haduvio Trial Results and Market Opportunities

Ryan DeschnerRaymond James

Raymond James

$29

Buy

384.95%

Upside

Reiterated

06/02/25

Raymond James Reaffirms Their Buy Rating on Trevi Therapeutics (TRVI)

Annabel SamimyStifel Nicolaus

Stifel Nicolaus

$15

Buy

150.84%

Upside

Reiterated

06/02/25

Buy Rating for Trevi Therapeutics: Promising Phase 2b Results for Haduvio in IPF-CC

Serge BelangerNeedham

Needham

$24

Buy

301.34%

Upside

Reiterated

06/02/25

Analysts Offer Insights on Healthcare Companies: Olema Pharmaceuticals (NASDAQ: OLMA) and Trevi Therapeutics (NASDAQ: TRVI)

Mayank MamtaniB.Riley Financial

B.Riley Financial

$20

Buy

234.45%

Upside

Reiterated

05/21/25

Kaveri PohlmanClear Street

Clear Street

$11

Buy

83.95%

Upside

Reiterated

03/06/25

Clear Street reiterates Buy Rating on Trevi Therapeutics (TRVI)Clear Street analyst Kaveri Pohlman reiterated a Buy rating and $11.00 price target on Trevi Therapeutics (NASDAQ: TRVI)

Jason KolbertD. Boral Capital

D. Boral Capital

$21

Buy

251.17%

Upside

Reiterated

10/04/24

EF Hutton reiterates Buy Rating on Trevi Therapeutics (TRVI)EF Hutton analyst Jason Kolbert reiterated a Buy rating and $21.00 price target on Trevi Therapeutics (NASDAQ: TRVI).

Stocks with the Highest Top Analyst Consensus in the Healthcare Sector

xxx

Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Trevi Therapeutics

1 Month

xxx

Success Rate

8/13 ratings generated profit

Average Return

+8.59%

reiterated a xxx

rating last month

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 1 Month would result in 61.54% of your transactions generating a profit, with an average return of +8.59% per trade.

3 Months

xxx

Success Rate

8/13 ratings generated profit

Average Return

+23.92%

reiterated a xxx

rating last month

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 3 Months would result in 61.54% of your transactions generating a profit, with an average return of +23.92% per trade.

1 Year

Mayank MamtaniB.Riley Financial

Success Rate

14/17 ratings generated profit

Average Return

+66.93%

reiterated a buy rating last month

Copying Mayank Mamtani's trades and holding each position for 1 Year would result in 82.35% of your transactions generating a profit, with an average return of +66.93% per trade.

2 Years

xxx

Success Rate

15/17 ratings generated profit

Average Return

+110.29%

reiterated a xxx

rating last month

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 2 Years would result in 88.24% of your transactions generating a profit, with an average return of +110.29% per trade.

The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

TRVI Analyst Recommendation Trends

Rating

Mar 25

Apr 25

May 25

Jun 25

Jul 25

Strong Buy

Buy

Hold

Sell

Strong Sell

total

In the current month, TRVI has received 21 Buy Ratings, 0 Hold Ratings, and 0 Sell Ratings. TRVI average Analyst price target in the past 3 months is 21.67.

Each month's total comprises the sum of three months' worth of ratings.

TRVI Financial Forecast

TRVI Earnings Forecast

Next quarter’s earnings estimate for TRVI is -$0.10 with a range of -$0.15 to -$0.07. The previous quarter’s EPS was -$0.09. TRVI beat its EPS estimate 50.00% of the time in the past 12 months, while its overall industry beat the EPS estimate 58.09% of the time in the same period. In the last calendar year TRVI has Outperformed its overall industry.

No data currently available

TRVI Sales Forecast

Next quarter’s sales forecast for TRVI is $0.00 with a range of $0.00 to $0.00. The previous quarter’s sales results were $0.00. TRVI beat its sales estimates 0.00% of the time in past 12 months, while its overall industry beat sales estimates 47.49% of the time in the same period. In the last calendar year TRVI has Preformed in-line its overall industry.

TRVI Stock Forecast FAQ

What is TRVI’s average 12-month price target, according to analysts?

Based on analyst ratings, Trevi Therapeutics’s 12-month average price target is 21.67.

What is TRVI’s upside potential, based on the analysts’ average price target?

Trevi Therapeutics has 262.37% upside potential, based on the analysts’ average price target.

Can I see which stocks the top-ranking analysts are rating?

Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.

How can I follow the stock ratings of top Wall Street analysts?

Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.

Is TRVI a Buy, Sell or Hold?

Trevi Therapeutics has a consensus rating of Strong Buy which is based on 9 buy ratings, 0 hold ratings and 0 sell ratings.

What is Trevi Therapeutics’s price target?

The average price target for Trevi Therapeutics is 21.67. This is based on 9 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst price target is $29.00 ,the lowest forecast is $13.00. The average price target represents 262.37% Increase from the current price of $5.98.

What do analysts say about Trevi Therapeutics?

Trevi Therapeutics’s analyst rating consensus is a Strong Buy. This is based on the ratings of 9 Wall Streets Analysts.

How can I buy shares of TRVI?

Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.

Become an Expert with TipRanks Premium

What am I Missing?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing

Trevi Therapeutics (TRVI) Stock Forecast & Price Target

TRVI Analyst Ratings

TRVI Stock 12 Month Forecast

Average Price Target

Detailed List of Analyst Forecasts​

Best Analysts Covering Trevi Therapeutics

TRVI Analyst Recommendation Trends

TRVI Financial Forecast

TRVI Earnings Forecast

TRVI Sales Forecast

TRVI Stock Forecast FAQ

Become an Expert with TipRanks Premium

Detailed List of Analyst Forecasts